Zobrazeno 1 - 10 of 62 pro vyhledávání: '"Qualls CW Jr"'
1
Akademický článek
Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes.
Autor: Terelius Y; Medivir AB, Stockholm, Sweden., Figler RA; HemoShear Therapeutics, 501 Locust Ave, Charlottesville, VA, 22902, USA., Marukian S; HemoShear Therapeutics, 501 Locust Ave, Charlottesville, VA, 22902, USA., Collado MS; HemoShear Therapeutics, 501 Locust Ave, Charlottesville, VA, 22902, USA., Lawson MJ; HemoShear Therapeutics, 501 Locust Ave, Charlottesville, VA, 22902, USA., Mackey AJ; HemoShear Therapeutics, 501 Locust Ave, Charlottesville, VA, 22902, USA., Manka D; HemoShear Therapeutics, 501 Locust Ave, Charlottesville, VA, 22902, USA., Qualls CW Jr; Qualls Preclinical Solutions LLC, 1943 Roadrunner Ave, Thousand Oaks, CA, 91320, USA., Blackman BR; HemoShear Therapeutics, 501 Locust Ave, Charlottesville, VA, 22902, USA., Wamhoff BR; HemoShear Therapeutics, 501 Locust Ave, Charlottesville, VA, 22902, USA., Dash A; HemoShear Therapeutics, 501 Locust Ave, Charlottesville, VA, 22902, USA. Electronic address: dash@hemoshear.com.
Publikováno v: Chemico-biological interactions [Chem Biol Interact] 2016 Aug 05; Vol. 255, pp. 31-44. Date of Electronic Publication: 2015 Dec 02.
Zobrazit plný text záznamu
2
Akademický článek
An In Vitro Cynomolgus Vascular Surrogate System for Preclinical Drug Assessment and Human Translation.
Autor: Cole BK; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Simmers MB; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Feaver R; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Qualls CW Jr; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Collado MS; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Berzin E; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Figler RA; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Pryor AW Jr; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Lawson M; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Mackey A; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Manka D; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Wamhoff BR; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Turk JR; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.)., Blackman BR; From the NASH Program (B.K.C., R.F.), Technology and Research Platforms (M.B.S.), Rare Diseases Program (M.S.C.), Vascular Program (E.B., D.M.), Pharmacology (R.A.F.), Cell Culture (A.W.P.), Computational Biology (M.L., A.M.), VP of Research and Development (B.R.W.), and Chief Scientific Officer (B.R.B.), HemoShear Therapeutics LLC, Charlottesville, VA (B.K.C., M.B.S., R.F., M.S.C., E.B., R.A.F., A.W.P., M.L., A.M., D.M., B.R.W, B.R.B.); and Comparative Biology and Safety Sciences (C.W.Q., J.R.T.), Amgen Inc, Thousand Oaks, CA (C.W.Q., J.R.T.). Blackman@HemoShear.com.
Publikováno v: Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2015 Oct; Vol. 35 (10), pp. 2185-95. Date of Electronic Publication: 2015 Aug 20.
Zobrazit plný text záznamu
3
Akademický článek
High-throughput secondary screening at the single-cell level.
Autor: Robinson JP; Purdue University Cytometry Laboratories, Department of Basic Medical Sciences, Purdue University, West Lafayette, IN 47907, USA. jpr@flowcyt.cyto.purdue.edu, Patsekin V, Holdman C, Ragheb K, Sturgis J, Fatig R, Avramova LV, Rajwa B, Davisson VJ, Lewis N, Narayanan P, Li N, Qualls CW Jr
Publikováno v: Journal of laboratory automation [J Lab Autom] 2013 Feb; Vol. 18 (1), pp. 85-98. Date of Electronic Publication: 2012 Sep 10.
Zobrazit plný text záznamu
4
Akademický článek
Differential mitochondrial toxicity screening and multi-parametric data analysis.
Autor: Tsiper MV; Bindley Bioscience Center at Purdue University Discovery Park, West Lafayette, Indiana, USA., Sturgis J, Avramova LV, Parakh S, Fatig R, Juan-García A, Li N, Rajwa B, Narayanan P, Qualls CW Jr, Robinson JP, Davisson VJ
Publikováno v: PloS one [PLoS One] 2012; Vol. 7 (10), pp. e45226. Date of Electronic Publication: 2012 Oct 15.
Zobrazit plný text záznamu
5
Akademický článek
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Autor: Morgan RE; Department of Comparative Biology and Safety Sciences Amgen Inc., Thousand Oaks, California 91320, USA., Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW Jr, Lightfoot-Dunn R, Hamadeh HK
Publikováno v: Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2010 Dec; Vol. 118 (2), pp. 485-500. Date of Electronic Publication: 2010 Sep 09.
Zobrazit plný text záznamu
6
Akademický článek
Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys.
Autor: Hoivik DJ; GlaxoSmithKline Pharmaceuticals, Five Moore Drive, Research Triangle Park, North Carolina, USA and Upper Merion, Pennsylvania, USA. debie.j.hoivik@gsk.com, Qualls CW Jr, Mirabile RC, Cariello NF, Kimbrough CL, Colton HM, Anderson SP, Santostefano MJ, Morgan RJ, Dahl RR, Brown AR, Zhao Z, Mudd PN Jr, Oliver WB Jr, Brown HR, Miller RT
Publikováno v: Carcinogenesis [Carcinogenesis] 2004 Sep; Vol. 25 (9), pp. 1757-69. Date of Electronic Publication: 2004 May 06.
Zobrazit plný text záznamu
7
Akademický článek
Frequent sampling reveals dynamic responses by the transcriptome to routine media replacement in HepG2 cells.
Autor: Morgan KT; GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA. kevin.morgan@aventis.com, Casey W, Easton M, Creech D, Ni H, Yoon L, Anderson S, Qualls CW Jr, Crosby LM, MacPherson A, Bloomfield P, Elston TC
Publikováno v: Toxicologic pathology [Toxicol Pathol] 2003 Jul-Aug; Vol. 31 (4), pp. 448-61.
Zobrazit plný text záznamu
8
Akademický článek
Effects of minimally toxic levels of carbonyl cyanide P-(trifluoromethoxy) phenylhydrazone (FCCP), elucidated through differential gene expression with biochemical and morphological correlations.
Autor: Kuruvilla S; Oklahoma State University, Stillwater, Oklahoma 74078, USA. Sabu.k.kuruvilla@gsk.com, Qualls CW Jr, Tyler RD, Witherspoon SM, Benavides GR, Yoon LW, Dold K, Brown RH, Sangiah S, Morgan KT
Publikováno v: Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2003 Jun; Vol. 73 (2), pp. 348-61. Date of Electronic Publication: 2003 Apr 15.
Zobrazit plný text záznamu
9
Akademický článek
Lymphoproliferative responses of splenocytes from wild cotton rats (Sigmodon hispidus) following acute exposure to Aroclor 1254.
Autor: Smith PN; The Institute of Environmental and Human Health, Texas Tech University/Texas Tech University Health Sciences Center, Box 41163, Lubbock, TX 79409-1163, USA., Lochmiller RL, Qualls CW Jr, Lish JW, McMurry ST
Publikováno v: Bulletin of environmental contamination and toxicology [Bull Environ Contam Toxicol] 2003 Jan; Vol. 70 (1), pp. 97-105.
Zobrazit plný text záznamu
10
Akademický článek
Application of cDNA microarray technology to in vitro toxicology and the selection of genes for a real-time RT-PCR-based screen for oxidative stress in Hep-G2 cells.
Autor: Morgan KT; Aventis Pharmaceuticals, Raleigh, North Carolina 27604, USA. kevin.morgan@aventis.com, Ni H, Brown HR, Yoon L, Qualls CW Jr, Crosby LM, Reynolds R, Gaskill B, Anderson SP, Kepler TB, Brainard T, Liv N, Easton M, Merrill C, Creech D, Sprenger D, Conner G, Johnson PR, Fox T, Sartor M, Richard E, Kuruvilla S, Casey W, Benavides G
Publikováno v: Toxicologic pathology [Toxicol Pathol] 2002 Jul-Aug; Vol. 30 (4), pp. 435-51.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje